Key result
Lower TAPSE/PAPs ratio linked to ~17% higher 2-year mortality and identifies combined pulmonary hypertension risk.
Why the study?
RV-PA uncoupling is a negative prognostic indicator in TAVR for severe AS, but its association with invasively determined PH subtypes required investigation to identify higher-risk patients.
Does the pre-procedural echocardiographic TAPSE/PAPs ratio predict combined pulmonary hypertension and 2-year all-cause mortality in patients undergoing TAVR for severe aortic stenosis?
Cohort (n=667)
No
Does the pre-procedural echocardiographic TAPSE/PAPs ratio predict combined pulmonary hypertension and 2-year all-cause mortality in patients undergoing TAVR for severe aortic stenosis?
Answers are grounded in this paper and cite their sources.
The echocardiographic TAPSE/PAPs ratio is a useful non-invasive marker to identify TAVR candidates at high risk for combined pulmonary hypertension and increased 2-year mortality, helping select patients who may benefit from right heart catheterization.
INTRODUCTION: Right ventricular-pulmonary artery (RV-PA) uncoupling, expressed as the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/PAPs) ratio, is a negative prognostic indicator in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS). This study aims to investigate the association between the echocardiographically measured TAPSE/PAPs ratio and invasively determined pulmonary hypertension (PH) subtypes in this population, with the goal of identifying patients at higher risk. METHODS: This study is a retrospective analysis of 667 patients who underwent TAVR for native severe symptomatic AS at our center between January 2015 and December 2022. All patients underwent a comprehensive transthoracic echocardiographic evaluation and right heart catheterization prior to the procedure. PH was classified into: no PH, isolated post-capillary PH (IpcPH), and combined pre- and post-capillary PH (CoPH). Follow-up time was defined as the time from the procedure to the last documented contact with the patient (alive) or to the time of documented death. All-cause mortality at two years was the primary endpoint. RESULTS: eTAPSE/PAPs showed a moderately positive correlation with pulmonary vascular resistance (Spearman's Rho = 0.52; p = 0.025) and was associated with CoPH (odds ratio 1.29, 95% confidence interval 1.10-1.30). ROC curve analysis showed that eTAPSE/PAPs discriminated presence of CoPH with an AUC of 0.740. The optimal cut-off value was 0.29 mm/mmHg (sensitivity 72%, specificity 60%). During follow-up, 157 deaths were recorded. Kaplan-Meier curves showed a significant difference in overall mortality at 2 years when patients were stratified according to eTPASE/PAPs ratio value of 0.29 (log rank = 4.94, p = 0.026). CONCLUSIONS: The eTAPSE/PAPs ratio identifies patients with symptomatic AS undergoing TAVR with higher risk of CoPH. These patients can benefit from an RHC to refine pre-operative risk assessment.
No takes yet. Share an insight, caveat, or question.
Putortì et al. (2026) conducted a cohort in Severe symptomatic aortic stenosis (n=667). Echocardiographic TAPSE/PAPs ratio vs. Higher TAPSE/PAPs ratio was evaluated on All-cause mortality at 2 years (HR 1.17, 95% CI 1.12-1.27, p=<0.01). A lower echocardiographic TAPSE/PAPs ratio identified patients at higher risk of combined pulmonary hypertension and was independently associated with increased 2-year all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: